# 2025年10月27日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 家用自动体外除颤器的有效性与成本效益：来自心脏骤停登记增强生存项目的报告

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41137600](https://pubmed.ncbi.nlm.nih.gov/41137600)
**期刊：** JAMA internal medicine
**PMID：** 41137600
**DOI：** 10.1001/jamainternmed.2025.6123

### 第一部分 原文与翻译

**英文原标题：** Effectiveness and Cost-Effectiveness of Automated External Defibrillators in Private Homes: A Report From the Cardiac Arrest Registry to Enhance Survival.

**英文摘要原文：**
IMPORTANCE: Automated external defibrillators (AEDs) have the potential to save lives when used during cardiac arrest. While most cardiac arrests occur at home, there is limited evidence for AED use in private homes.

OBJECTIVE: To determine whether AEDs in private homes are effective and cost-effective.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used observational data from the Cardiac Arrest Registry to Enhance Survival in the US from January 2017 to December 2024 to determine the effectiveness of AEDs when used for cardiac arrests in private homes. A difference-in-difference approach was used to determine the causal relationship between AED application and survival to hospital discharge. A decision-analytic model was then created to evaluate the cost-effectiveness of purchasing an AED in a private home in the US.

EXPOSURE: Application of an AED.

MAIN OUTCOMES AND MEASURES: Survival to hospital discharge and cost-effectiveness.

RESULTS: Of 582 536 included patients, 359 809 (61.8%) were male, and the median (IQR) age was 65 (52-76) years. Survival was better with AED application compared with no AED application in patients with a shockable rhythm (risk ratio, 1.26; 95% CI, 1.01-1.57) but not in those with a nonshockable rhythm (risk ratio, 1.00; 95% CI, 0.68-1.46). Results were consistent in the difference-in-difference analysis. The incremental cost-effectiveness ratio for an AED in a private home was $4 481 659 per quality-adjusted life-year. At a cost-effectiveness threshold of $200 000 per quality-adjusted life-year, AEDs in private homes would be considered cost-effective at a yearly cardiac arrest incidence per person above 1.3% or at an AED cost less than $65 (not including bystander training cost).

CONCLUSIONS AND RELEVANCE: In this study, AEDs in private homes were effective at improving outcomes for patients with cardiac arrest and a shockable rhythm. Given the relative rarity of cardiac arrest at a given home, general purchase of AEDs for individual private homes cannot be considered cost-effective at the current pricing of AEDs.

**中文摘要译文：**
重要性：自动体外除颤器（AEDs）在心脏骤停期间使用有挽救生命的潜力。虽然大多数心脏骤停发生在家庭中，但关于AED在私人住宅中使用的证据有限。

目的：确定私人住宅中的AED是否有效且具有成本效益。

设计、设置和参与者：这项队列研究使用了2017年1月至2024年12月美国心脏骤停登记增强生存项目的观察数据，以确定AED在私人住宅中用于心脏骤停时的有效性。采用双重差分法来确定AED应用与出院生存率之间的因果关系。随后建立了一个决策分析模型来评估在美国私人住宅购买AED的成本效益。

暴露因素：AED的应用。

主要结局和指标：出院生存率和成本效益。

结果：在纳入的582,536名患者中，359,809名（61.8%）为男性，中位年龄（四分位距）为65（52-76）岁。对于可电击心律的患者，使用AED的生存率优于不使用AED（风险比1.26；95%置信区间1.01-1.57），但对于不可电击心律的患者则无此差异（风险比1.00；95%置信区间0.68-1.46）。双重差分分析结果一致。私人住宅中AED的增量成本效益比为每质量调整生命年4,481,659美元。在以每质量调整生命年200,000美元的成本效益阈值下，私人住宅中的AED在每人每年心脏骤停发生率高于1.3%或AED成本低于65美元（不包括旁观者培训成本）时才能被认为是成本有效的。

结论与相关性：在本研究中，私人住宅中的AED对于改善心脏骤停且为可电击心律患者的预后是有效的。鉴于特定家庭中心脏骤停的相对罕见性，在当前AED定价下，为单个私人住宅普遍购买AED不能被认为是成本有效的。

### 第二部分 AI 大师评价

本研究通过大规模队列数据和双重差分方法，系统评估了家用自动体外除颤器的临床价值与经济性。研究创新性地结合了真实世界证据与决策分析模型，填补了家庭环境中AED应用证据的空白。关键发现显示AED对可电击心律患者具有显著生存获益（风险比1.26），但成本效益分析表明在当前定价下难以实现经济合理性。这一研究为公共卫生政策制定提供了重要依据，提示应针对高风险人群或通过降低设备成本来优化资源配置策略。

---

## 2. 阻塞性睡眠呼吸暂停的药物治疗：前景与挑战

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41077051](https://pubmed.ncbi.nlm.nih.gov/41077051)
**期刊：** Lancet (London, England)
**PMID：** 41077051
**DOI：** 10.1016/S0140-6736(25)01379-0

### 第一部分 原文与翻译

**英文原标题：** Drug therapy for obstructive sleep apnoea: promises and challenges.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于阻塞性睡眠呼吸暂停（OSA）的药物治疗领域，系统探讨了该治疗策略的发展前景与面临挑战。虽然无法获取详细的研究方法和具体发现，但从标题可推断该研究可能综述了现有药物干预的疗效、安全性及临床应用价值。该主题具有重要的临床意义，因为传统持续气道正压通气治疗存在依从性问题，药物治疗可能为患者提供替代选择。然而，药物干预OSA仍面临诸多挑战，包括疗效稳定性、长期安全性以及个体化治疗策略的制定等关键问题。

---

## 3. 产后出血临床指标预测孕产妇死亡或严重发病的预后准确性：WHO个体参与者数据荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41056961](https://pubmed.ncbi.nlm.nih.gov/41056961)
**期刊：** Lancet (London, England)
**PMID：** 41056961
**DOI：** 10.1016/S0140-6736(25)01639-3

### 第一部分 原文与翻译

**英文原标题：** Prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity: a WHO individual participant data meta-analysis.

**英文摘要原文：**
BACKGROUND: Postpartum haemorrhage (excessive bleeding after birth) is a leading cause of maternal mortality and morbidity worldwide. However, there is no global consensus on which clinical markers best define excessive bleeding or reliably predict adverse maternal outcomes. The aim of this study was to assess the prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity.

METHODS: In this individual participant data meta-analysis, eligible datasets were identified through a global call for data issued by WHO and systematic searches of PubMed, MEDLINE, Embase, the Cochrane Library, and WHO trial registries (from database inception to Nov 6, 2024). Studies were eligible if they included at least 200 participants with objectively measured blood loss or other clinical markers of haemodynamic instability, and reported at least one clinical outcome of interest. Individual participant data were requested for all eligible studies. For each dataset, we computed the prognostic accuracy of each clinical marker to predict a composite outcome of maternal mortality or severe morbidity (blood transfusion, surgical interventions, or admission to intensive care unit). Five clinical markers were assessed: measured blood loss, pulse rate, systolic blood pressure, diastolic blood pressure, and shock index. Results were meta-analysed through two-level mixed-effects logistic regression models, with a bivariate normal model used to generate summary accuracy estimates. Clinical marker and threshold selections were informed by a WHO expert consensus process, which placed emphasis on maximising prognostic sensitivity (preferably >80%) over prognostic specificity (preferably ≥50%). This meta-analysis was registered on PROSPERO (CRD420251034918).

FINDINGS: We identified 33 potentially eligible datasets and successfully obtained and analysed full data for 12 datasets, comprising 312 151 women. At the conventional threshold of 500 mL, measured blood loss had a summary prognostic sensitivity of 75·7% (95% CI 60·3-86·4) and specificity of 81·4% (95% CI 70·7-88·8) for predicting the composite outcome. The preferred sensitivity threshold was reached at 300 mL (83·9% [95% CI 72·8-91·1]), although at the expense of reduced specificity (54·8% [95% CI 38·0-70·5]). Prognostic performance improved with a decision rule that combined the use of either blood loss thresholds less than 500 mL (≥300 mL to ≥450 mL) and any abnormal haemodynamic sign (pulse rate >100 beats per min, systolic blood pressure <100 mm Hg, diastolic blood pressure <60 mm Hg, or shock index >1·0) or 500 mL or more of blood loss, with sensitivities ranging from 86·9% to 87·9% and specificities from 66·6% to 76·1%.

INTERPRETATION: Measured blood loss below the conventional threshold, combined with abnormal haemodynamic signs, accurately predicts women at risk of death or life-threatening complications from postpartum bleeding and could support earlier postpartum haemorrhage diagnosis and treatment.

FUNDING: The Gates Foundation and UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction.

**中文摘要译文：**
背景：产后出血（分娩后过度出血）是全球孕产妇死亡和发病的主要原因。然而，关于哪些临床指标最能定义过度出血或可靠预测不良孕产妇结局，目前尚无全球共识。本研究旨在评估产后出血临床指标预测孕产妇死亡或严重发病的预后准确性。

方法：在这项个体参与者数据荟萃分析中，通过WHO发布的全球数据征集以及系统检索PubMed、MEDLINE、Embase、Cochrane图书馆和WHO试验注册库（从数据库建立至2024年11月6日）来确定符合条件的数据集。研究符合条件需包括至少200名具有客观测量失血量或其他血流动力学不稳定临床指标的参与者，并报告至少一个关注的临床结局。我们要求所有符合条件的研究提供个体参与者数据。对于每个数据集，我们计算了每个临床指标预测孕产妇死亡或严重发病复合结局（输血、手术干预或入住重症监护室）的预后准确性。评估了五个临床指标：测量失血量、脉搏率、收缩压、舒张压和休克指数。通过两级混合效应逻辑回归模型进行荟萃分析，使用双变量正态模型生成汇总准确性估计值。临床指标和阈值选择基于WHO专家共识过程，该过程强调最大化预后敏感性（优选>80%）优于预后特异性（优选≥50%）。本荟萃分析已在PROSPERO注册（CRD420251034918）。

发现：我们确定了33个可能符合条件的数据集，并成功获取并分析了12个数据集的完整数据，包括312,151名女性。在传统的500 mL阈值下，测量失血量预测复合结局的汇总预后敏感性为75.7%（95% CI 60.3-86.4），特异性为81.4%（95% CI 70.7-88.8）。优选敏感性阈值在300 mL时达到（83.9% [95% CI 72.8-91.1]），尽管以特异性降低为代价（54.8% [95% CI 38.0-70.5]）。采用结合使用低于500 mL的失血阈值（≥300 mL至≥450 mL）和任何异常血流动力学体征（脉搏率>100次/分、收缩压<100 mm Hg、舒张压<60 mm Hg或休克指数>1.0）或500 mL及以上失血量的决策规则，预后性能得到改善，敏感性范围为86.9%至87.9%，特异性范围为66.6%至76.1%。

解释：低于传统阈值的测量失血量结合异常血流动力学体征，能准确预测因产后出血面临死亡或危及生命并发症风险的女性，并可支持更早的产后出血诊断和治疗。

资助：盖茨基金会和联合国开发计划署/联合国人口基金/联合国儿童基金会/世界卫生组织/世界银行人类生殖研究、发展和研究培训特别规划。

### 第二部分 AI 大师评价

本研究通过WHO主导的大规模个体参与者数据荟萃分析，系统评估了产后出血临床指标的预后准确性，填补了全球缺乏统一诊断标准的空白。研究创新性地采用个体参与者数据荟萃方法，纳入了超过31万女性的数据，通过多水平混合效应模型提供了更精确的准确性估计。关键发现表明，结合低于传统阈值的失血量（300-450mL）与异常血流动力学体征的决策规则，能显著提高预测敏感性至87%左右，为临床实践提供了更优的风险分层工具。该研究具有重要的临床转化价值，有望推动产后出血早期识别和干预策略的标准化，但研究仅基于现有数据集，未来需要前瞻性验证这些决策规则的实际临床效果。

---

速递结束，祝您工作愉快！